Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 26Thoracic 2Head & Neck 2Genitourinary 2Breast 2Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Breast Neoplasms 166Triple Negative Breast Neoplasms 54Neoplasm Metastasis 23Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 15Ovarian Neoplasms 11Colorectal Neoplasms 9Small Cell Lung Carcinoma 8Sarcoma 8Neoplasms 8Lung Neoplasms 8Prostatic Neoplasms 7Colonic Neoplasms 7Breast Neoplasms, Male 7Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Head and Neck Neoplasms 4Urinary Bladder Neoplasms 3Recurrence 3Rectal Neoplasms 3Multiple Myeloma 3Melanoma 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2

Interventions

pembrolizumab 16Cyclophosphamide 9Nivolumab 7atezolizumab 6fludarabine 5Specimen Handling 5Magnetic Resonance Spectroscopy 5cabozantinib 4Trastuzumab 4budigalimab 3Ipilimumab 3Interleukin-2 3Cisplatin 3Capecitabine 3Albumin-Bound Paclitaxel 3spartalizumab 2sargramostim 2poly ICLC 2palbociclib 2lenvatinib 2epacadostat 2durvalumab 2avelumab 2X-Rays 2Sunitinib 2Paclitaxel 2Irinotecan 2Interleukin-12 2Immunoglobulin G 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Gemcitabine × Breast × Clear all
NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Gossamer Bio Inc.

Phase 1 Terminated
61 enrolled
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡